MEGACE
LOE ApproachingNDAORALSUSPENSION
Approved
Sep 1993
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
4/8 — Partial
MEGACE by Bristol Myers Squibb is cachexia. Approved for anorexia, cachexia, an unexplained significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (aids). First approved in 1993.
Drug data last refreshed 22h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MEGACE is an oral suspension containing megestrol acetate approved in 1993 for treating anorexia, cachexia, and unexplained weight loss in AIDS patients. The precise mechanism of action remains unknown, though it is hypothesized to work through appetite stimulation and metabolic modulation. This small-molecule product addresses a critical palliative need in advanced HIV/AIDS care.
LOE Approaching
As LOE approaches, the brand team is likely contracting; roles may shift toward generic transition support or related indication development within Bristol Myers Squibb's portfolio.
Worked on MEGACE at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.